Do peptides help with tendon injury and tendinopathy?
3 peptides are graded for tendon injury and tendinopathy on this page. The strongest grade is animal-only evidence, for BPC-157, TB-500, and GHK-Cu. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for tendon injury and tendinopathy?
Progressive loading and eccentric exercise, activity modification, and time; short courses of NSAIDs for pain; physical therapy. Corticosteroid injection gives short term relief but can weaken tendon. Platelet rich plasma and surgery are considered for refractory cases.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for tendon injury and tendinopathy?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| BPC-157 | Evidence: Animal-only evidence | Faster Achilles tendon healing and increased tendon cell outgrowth in rats; no human RCT. [1] [2] |
| TB-500 | Evidence: Animal-only evidence | The rat wound closure and cell migration results cited here came from full-length thymosin beta-4, not TB-500. TB-500 itself has not been tested for tendon healing in animals or people. [3] |
| GHK-Cu | Evidence: Animal-only evidence | Collagen synthesis and remodeling effects in animal and cell models; human data limited to skin. [4] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Do peptides help tendon repair?
Not in any published human trial. BPC-157 sped Achilles tendon healing in rats, and GHK-Cu shows tissue repair effects in animal and cell models. The repair results often credited to TB-500 came from full-length thymosin beta-4, which FDA says is not the same substance, and TB-500 itself has not been tested for tendon healing. None has a randomized human trial for tendon injury. [1] [2] [3] [4]
Is any peptide FDA approved for tendon injury and tendinopathy?
No. None of the peptides graded for tendon injury and tendinopathy is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [5]
Has any peptide been tested in a randomized trial for tendon injury and tendinopathy?
No. The best evidence for any peptide graded for tendon injury and tendinopathy is animal only evidence, so none has been shown to work in a randomized human trial for this use. [1] [2] [3] [4]
Is BPC-157 legal?
BPC-157 is not an FDA approved drug and is not on the 503A bulks list; its nomination was withdrawn in April 2026. FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds single-ingredient BPC-157 by an allowed route on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer. The draft is not binding, does not cover blends, and HHS may revisit it. Products sold as research chemicals for human use are still unapproved drugs. [6] [7] [8] [9]
From the blog
- Peptides for tendon recovery, ranked by human evidence
BPC-157, TB-500, GHK-Cu, PEG-MGF, and IGF-1 LR3 ranked by our evidence grades. None has a published human tendon trial. Here is the ranking, the reasoning, and what does have human data.
- BPC-157 and cancer: what the evidence shows
Does BPC-157 cause cancer or feed tumors? The concern is theoretical, based on blood vessel growth in animal studies. No human study has assessed it, and FDA found no carcinogenicity data.
- TB-500 side effects and benefits: what the evidence shows
No human study of TB-500 has been published, so its side effects in people are unknown. What FDA's 2026 review found, which studies tested a different peptide, and its legal status.
- BPC-157 before and after: reviews, results, and what controlled studies show
BPC-157 reviews and before and after stories are everywhere. Controlled results exist only in rats. What the animal healing timelines show, what the human pilots found, and why anecdotes mislead.
- BPC-157 capsules and pills: what oral BPC-157 was tested for, and what is missing
BPC-157 capsules and pills rest on rat gut, ligament, and fistula studies. No study has measured how much a capsule absorbs in people, and the two registered oral studies have posted no results.
- BPC-157 human studies: every published report and registered clinical trial
Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.
Sources
- [1]The promoting effect of pentadecapeptide BPC 157 on tendon healing (J Appl Physiol 2011)PubMed 21030672, 2011
- [2]BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
- [3]Thymosin beta4 accelerates wound healingPubMed 10469335, 1999
- [4]Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene dataPubMed 29986520, 2018
- [5]Drugs@FDA: FDA-approved drugs databaseFDA
- [6]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
- [7]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [8]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, HHS notice of availability of a draft policy, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496 (public inspection copy; publication scheduled October 30, 2026)Federal Register, 2026
- [9]HHS: draft enforcement discretion policy for 503A compounding using certain peptide bulk drug substances, with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history), October 28, 20262026